Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
Gómez-Dabó, Laura (Hospital Universitari Vall d'Hebron)
Caronna, Edoardo (Hospital Universitari Vall d'Hebron)
Mas-de-les-Valls, Rut (Vall d'Hebron Institut de Recerca (VHIR))
Gallardo López, Victor José (Vall d'Hebron Institut de Recerca (VHIR))
Alpuente, Alicia (Vall d'Hebron Institut de Recerca (VHIR))
Torres-Ferrús, Marta (Vall d'Hebron Institut de Recerca (VHIR))
Pozo-Rosich, Patricia (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2024
Resum:	Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days-MHD; monthly migraine days-MMD; acute medication days/month-AMDM) and side effect data were collected. A ≥ 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14. 75-17], 70% (14/20) females). The median basal frequencies were 28. 8 [20-28] MHD, 18 [10-28] MMD and 10 [7. 5-21. 2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of -20 days/month (p = 0. 001). At 12 months (n = 14), eight patients (57. 1%) were responders, with a median reduction in MHD of -17. 5 days/month (p = 0. 002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Migraine ; onabotulinumtoxinA ; Adolescents ; Teenagers ; Children
Publicat a:	Toxins, Vol. 16 Núm. 5 (May 2024) , ISSN 2072-6651

DOI: 10.3390/toxins16050221
PMID: 38787073

12 p, 913.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats